Steffen Schmitz-Valckenberg
Rating: 4.7 of 5
( out of 572 reviews )

Steffen Schmitz-Valckenberg, MD

Languages spoken: German, English

Clinical Locations

Primary Location

Farmington Health Center

165 N. University Ave.
Farmington , UT 84025
801-213-3200
Get Directions

John A. Moran Eye Center

65 N Mario Capecchi
Salt Lake City , UT 84132
801-581-2352
Get Directions

Midvalley Health Center

Moran Eye Center
243 East 6100 South
Murray , UT 84107
801-585-3937
Get Directions

  • Steffen Schmitz-Valckenberg, MD, specializes in clinical and surgical treatment of macular and retinal diseases, including age-related macular degeneration (AMD), and is an expert in high-resolution retinal imaging.

    Dr. Schmitz-Valckenberg co-founded and directed the Grading of Digital Fundus Examination Reading Center at the University of Bonn, Germany, where he was the Department of Ophthalmology’s assistant medical director. As an expert in high-resolution retinal and fundus autofluorescence imaging, he has used various imaging techniques to map the stages of decline in AMD. Researchers worldwide use this mapping to measure outcomes during interventional clinical trials.

    At Moran, Dr. Schmitz-Valckenberg is directing an ophthalmic image reading center that will play a key role in the Sharon Eccles Steele Center for Translational Medicine's drive to take a new therapy for a prevalent form of AMD into clinical trials.

    Dr. Schmitz-Valckenberg holds a Jon M. Huntsman Presidential Chair at the University of Utah and is a prolific researcher with more than 165 publications and 120 peer-reviewed articles. His honors include being named by The Ophthalmologist to its Power List 2017: Top 50 Rising Stars.

    Get to know Dr. Schmitz-Valckenberg by watching his profile video.

    Specialties

    Board Certification

    European Board of Ophthalmology
    Medical Association of North Rhine-Ophthalmology

    Patient Rating

    Rating: 4.7 out of 5
    4.7 /5
    ( out of 572 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    December 17, 2025
    MORAN EYE CENTER
    Rating: 5 out of 5

    I'm glad.tohave.found him

    December 15, 2025
    MORAN EYE CENTER
    Rating: 5 out of 5

    Direct but kind. Listens and patiently answers all my questions. So grateful I found him!

    December 14, 2025
    MORAN EYE CENTER
    Rating: 5 out of 5

    I was real pleased with the doctor and the staff. It took care of me concerned about my eye that makes you feel special good job

    December 13, 2025
    FARMINGTON HEALTH CENTER
    Rating: 5 out of 5

    Best Dr ever

    December 11, 2025
    FARMINGTON HEALTH CENTER
    Rating: 5 out of 5

    I appreciate Dr. Schmitz-Valckenberg's clear communication and thoughtful care. His fellow, Dr. Katzburg, is also very good.

    December 11, 2025
    MORAN EYE CENTER
    Rating: 5 out of 5

    Explained the surgery so I could understand it and the few, if any, chances of infection etc. I have trust in the people involved with this invasive procedure.

    December 10, 2025
    MORAN EYE CENTER
    Rating: 5 out of 5

    Dr. Schmitz-Valckenberg is first rate!

    November 28, 2025
    FARMINGTON HEALTH CENTER
    Rating: 5 out of 5

    Efficient

    November 26, 2025
    MORAN EYE CENTER
    Rating: 4 out of 5

    Explaining without prompting all the medical issues would be very much appreciated.

  • Steffen Schmitz-Valckenberg, MD, specializes in clinical and surgical treatment of macular and retinal diseases, including age-related macular degeneration (AMD), and is an expert in high-resolution retinal imaging.

    Dr. Schmitz-Valckenberg co-founded and directed the Grading of Digital Fundus Examination Reading Center at the University of Bonn, Germany, where he was the Department of Ophthalmology’s assistant medical director. As an expert in high-resolution retinal and fundus autofluorescence imaging, he has used various imaging techniques to map the stages of decline in AMD. Researchers worldwide use this mapping to measure outcomes during interventional clinical trials.

    At Moran, Dr. Schmitz-Valckenberg is directing an ophthalmic image reading center that will play a key role in the Sharon Eccles Steele Center for Translational Medicine's drive to take a new therapy for a prevalent form of AMD into clinical trials.

    Dr. Schmitz-Valckenberg holds a Jon M. Huntsman Presidential Chair at the University of Utah and is a prolific researcher with more than 165 publications and 120 peer-reviewed articles. His honors include being named by The Ophthalmologist to its Power List 2017: Top 50 Rising Stars.

    Get to know Dr. Schmitz-Valckenberg by watching his profile video.

    Board Certification and Academic Information

    Academic Departments Ophthalmology & Visual Sciences -Professor
    Board Certification
    European Board of Ophthalmology
    Medical Association of North Rhine-Ophthalmology

    Education history

    Professional Medical Medicine - Ruprecht-Karls-University Heidelberg M.D.

    Selected Publications

    Journal Article

    1. Schloesser L, Terheyden JH, Behning C, Klinkhammer H, Garzone D, Samannshausen M, Thiele S, Schmitz-Valckenberg S, Hoyng C, Snchez CI, Schmid M, Luhmann UFO, Floyd H, Leal S, Holz FG, Finger RP, MACUSTAR Consortium (2025). Associations Between Structural Phenotype and Polygenic Risk Scores in Intermediate Age-Related Macular Degeneration - A MACUSTAR Report. Transl Vis Sci Technol, 14(9), 37. (Read full publication)
    2. Heimes-Bussmann B, Bellenbaum R, Njoo C, Liakopoulos S, Schmitz-Valckenberg S, Zortel M, Rothaus K, Leemhuis J, Mussinghoff P, Lommatzsch A (2025). [Faricimab in previously treated neovascular age-related macular degeneration : Study design of the prospective noninterventional study PASSENGER]. Ophthalmologie, 122(9), 693-699. (Read full publication)
    3. Wu Z, Blodi BA, Holz FG, Jaffe GJ, Liakopoulos S, Sadda SR, Schmitz-Valckenberg S, Bonse M, Brown T, Choong J, Clifton B, Corradetti G, Hodgson LAB, Lentzsch AM, Mahmoudi A, Pak JW, Samannshausen M, Skalak C, von der Emde L, Winkler J, Guymer RH (2025). OCT-Defined Atrophic Age-Related Macular Degeneration Changes Associated with Deep Visual Sensitivity Losses: A Multicenter Study. Ophthalmol Sci, 5(6), 100884. (Read full publication)
    4. Liermann YN, Behning C, Isselmann B, Schmid M, Dunbar HMP, Luhmann UFO, Finger RP, Schmitz-Valckenberg S, Holz FG, Pfau M, Luu CD, Samannshausen M, Thiele S, MACUSTAR consortium (2025). Ellipsoid zone reflectivity as a functional imaging biomarker for age-related macular degeneration: a MACUSTAR study report. Sci Rep, 15(1), 20093. (Read full publication)
    5. Wu Z, Sadda SR, Ach T, Blodi BA, Bottoni F, Chakravarthy U, Chew EY, Curcio CA, Ferris FL 3rd, Fleckenstein M, Freund KB, Grunwald JE, Holz FG, Jaffe GJ, Liakopoulos S, Lim TH, Mons JM, Pagliarini S, Pauleikhoff D, Pfau M, Rosenfeld PJ, Sarraf D, Schmitz-Valckenberg S, Spaide RF, Sparrow JR, Staurenghi G, Tufail A, Viola F, Guymer RH (2025). Onset of End-Stage Atrophic Age-Related Macular Degeneration as an End Point-A Delphi Study: Classification of Atrophy Meetings Report 7. Ophthalmol Sci, 5(5), 100777. (Read full publication)
    6. Terheyden JH, Holz FG, Behning C, Dunbar HMP, Schmitz-Valckenberg S, Tufail A, Schmid M, Crabb DP, Samannshausen M, Binns A, Hoyng CB, Zakaria N, Poor S, Moll KP, Cosette D, Martinho C, Batuca J, Cunha-Vaz J, Luhmann UFO, Leal S, Finger RP, MACUSTAR consortium (2025). The Spectrum of Functional, Structural, and Patient-Reported Outcomes in Intermediate Age-Related Macular Degeneration: A MACUSTAR Study Report. Ophthalmologica, 1-11. (Read full publication)
    7. Anegondi N, Steffen V, Sadda SR, Schmitz-Valckenberg S, Tufail A, Csaky K, Lad EM, Kaiser PK, Ferrara D, Chakravarthy U (2024). Visual Loss in Geographic Atrophy: Learnings from the Lampalizumab Trials. Ophthalmology. (Read full publication)
    8. de Vente C, Valmaggia P, Hoyng CB, Holz FG, Islam MM, Klaver CCW, Boon CJF, Schmitz-Valckenberg S, Tufail A, Samannshausen M, Snchez CI, MACUSTAR Consortium (2024). Generalizable Deep Learning for the Detection of Incomplete and Complete Retinal Pigment Epithelium and Outer Retinal Atrophy: A MACUSTAR Report. Transl Vis Sci Technol, 13(9), 11. (Read full publication)
    9. Knzel SH, Broadbent E, Mller PT, Lindner M, Goerdt L, Czauderna J, Schmitz-Valckenberg S, Holz FG, Pfau M, Fleckenstein M (2024). Association of Lesion Location and Functional Parameters with Vision-Related Quality of Life in Geographic Atrophy Secondary to Age-related Macular Degeneration. Ophthalmol Retina, 8(8), 794-803. (Read full publication)
    10. Samannshausen M, Dngelci S, Vaisband M, von der Emde L, Sloan KR, Hasenauer J, Holz FG, Schmitz-Valckenberg S, Ach T (2024). Spatially Resolved Association of Structural Biomarkers on Retinal Function in Non-Exudative Age-Related Macular Degeneration Over 4 Years. Invest Ophthalmol Vis Sci, 65(4), 45. (Read full publication)
    11. Zouache MA, Richards BT, Pappas CM, Anstadt RA, Liu J, Corsetti T, Matthews S, Seager NA, Schmitz-Valckenberg S, Fleckenstein M, Hubbard WC, Thomas J, Hageman JL, Williams BL, Hageman GS (2024). Levels of complement factor H-related 4 protein do not influence susceptibility to age-related macular degeneration or its course of progression. Nat Commun, 15(1), 443. (Read full publication)
    12. Guymer R, Bailey C, Chaikitmongkol V, Chakravarthy U, Chaudhary V, Finger RP, Gallego-Pinazo R, Chuan AKH, Ishida S, Lvestam-Adrian M, Parravano M, Luna Pinto JD, Schmitz-Valckenberg S, Sheth V, Souied EH, Chi GC, Gilberg F, Glittenberg C, Scheidl S, Bengus M (2023). Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice. Ophthalmol Sci, 4(3), 100442. (Read full publication)
    13. von der Emde L, Mallwitz M, Vaisband M, Hasenauer J, Samannshausen M, Terheyden JH, MACUSTAR Consortium, Sloan KR, Schmitz-Valckenberg S, Finger RP, Holz FG, Ach T (2023). Retest variability and patient reliability indices of quantitative fundus autofluorescence in age-related macular degeneration: a MACUSTAR study report. Sci Rep, 13(1), 17417. (Read full publication)
    14. Knzel SH, Broadbent E, Mller PT, Lindner M, Goerdt L, Czauderna J, Schmitz-Valckenberg S, Holz FG, Pfau M, Fleckenstein M (2023). Impact of lesion location and functional parameters on vision-related quality of life in geographic atrophy secondary to AMD. (Read full publication)
    15. Weber C, Stasik I, Herrmann P, Schmitz-Valckenberg S, Holz FG, Liegl R (2023). Early Vitrectomy with Silicone Oil Tamponade in the Management of Postoperative Endophthalmitis. J Clin Med, 12(15). (Read full publication)
    16. Schmitz-Valckenberg S, Samannshausen M, Braun M, Steffen V, Gao SS, Honigberg L, Ferrara D, Pfau M, Holz FG (2023). Inter-Reader Agreement and Longitudinal Progression of Incomplete/Complete Retinal Pigment Epithelium and Outer Retinal Atrophy in AMD. Ophthalmol Retina. (Read full publication)
    17. Spaide T, Jiang J, Patil J, Anegondi N, Steffen V, Kawczynski MG, Newton EM, Rabe C, Gao SS, Lee AY, Holz FG, Sadda S, Schmitz-Valckenberg S, Ferrara D (2023). Geographic Atrophy Segmentation Using Multimodal Deep Learning. Transl Vis Sci Technol, 12(7), 10. (Read full publication)
    18. Wu Z, Schmitz-Valckenberg S, Blodi BA, Holz FG, Jaffe GJ, Liakopoulos S, Sadda SR, Bonse M, Brown T, Choong J, Clifton B, Corradetti G, Corvi F, Dieu AC, Dooling V, Pak JW, Samannshausen M, Skalak C, Thiele S, Guymer RH (2023). Reticular Pseudodrusen: Interreader Agreement of Evaluation on OCT Imaging in Age-Related Macular Degeneration. Ophthalmol Sci, 3(4), 100325. (Read full publication)
    19. Dhooge PPA, Mller PT, Meland N, Stingl K, Boon CJF, Lotery AJ, Parodi MB, Herrmann P, Klein W, Fsadni MG, Wheeler-Schilling TH, Holz FG, Hoyng CB, Schmitz-Valckenberg S, Soraprazan Consortium (2023). Repeatability of Quantitative Autofluorescence Imaging in a Multicenter Study Involving Patients With Recessive Stargardt Disease 1. Transl Vis Sci Technol, 12(2), 1. (Read full publication)
    20. Samannshausen M, Behning C, Weinz J, Goerdt L, Terheyden JH, Chang P, Schmid M, Poor SH, Zakaria N, Finger RP, Holz FG, Pfau M, Schmitz-Valckenberg S, Thiele S, MACUSTAR consortium members (2022). Characteristics and Spatial Distribution of Structural Features in Age-Related Macular Degeneration: A MACUSTAR Study Report. Ophthalmol Retina. (Read full publication)
    21. Garzone D, Terheyden JH, Morelle O, Wintergerst MWM, Samannshausen M, Schmitz-Valckenberg S, Pfau M, Thiele S, Poor S, Leal S, Holz FG, Finger RP, MACUSTAR Consortium (2022). Comparability of automated drusen volume measurements in age-related macular degeneration: a MACUSTAR study report. Sci Rep, 12(1), 21911. (Read full publication)
    22. Pfau M, Schmitz-Valckenberg S, Ribeiro R, Safaei R, McKeown A, Fleckenstein M, Holz FG (2022). Association of complement C3 inhibitor pegcetacoplan with reduced photoreceptor degeneration beyond areas of geographic atrophy. Sci Rep, 12(1), 17870. (Read full publication)
    23. Dhooge PPA, Mller PT, Boon CJF, Lotery AJ, Herrmann P, Battaglia Parodi M, Klein W, Fsadni MG, Wheeler-Schilling TH, Jungmann O, Mller H, Holz FG, Schmitz-Valckenberg S, Peters TM, Stingl K, Hoyng CB, Soraprazan Consortium (2022). The STArgardt Remofuscin Treatment Trial (STARTT): design and baseline characteristics of enrolled Stargardt patients. Open Res Eur, 1, 96. (Read full publication)
    24. Faatz H, Feltgen N, Gutfleisch M, Heimes-Bussmann B, Krohne TU, Liakopoulos S, Liegl R, Lommatzsch A, Mussinghoff P, Rehak M, Schmitz-Valckenberg S, Spital G, Stanzel B, Ziemssen F, Hgele B, Junkes C, Porstner M, Vgeler J, Gmeiner B, Pauleikhoff D (2022). [Prospective noninterventional BLUE SKY study evaluating the efficacy of brolucizumab in treatment-naïve and previously treated patients with neovascular AMD]. Ophthalmologie. (Read full publication)
    25. Samannshausen M, Behning C, Isselmann B, Schmid M, Finger RP, Holz FG, Schmitz-Valckenberg S, Pfau M, MACUSTAR Consortium, Thiele S (2022). Relative ellipsoid zone reflectivity and its association with disease severity in age-related macular degeneration: a MACUSTAR study report. Sci Rep, 12(1), 14933. (Read full publication)
    26. Bindewald-Wittich A, Dolar-Szczasny J, Kuenzel SH, von der Emde L, Pfau M, Rejdak R, Schmitz-Valckenberg S, Ach T, Dreyhaupt J, Holz FG (2022). Blue-light fundus autofluorescence imaging of pigment epithelial detachments. Eye (Lond). (Read full publication)
    27. Samannshausen M, Thiele S, Behning C, Pfau M, Schmid M, Leal S, Luhmann UFO, Finger RP, Holz FG, Schmitz-Valckenberg S, MACUSTAR Consortium (2022). Intersession Repeatability of Structural Biomarkers in Early and Intermediate Age-Related Macular Degeneration: A MACUSTAR Study Report. Transl Vis Sci Technol, 11(3), 27. (Read full publication)
    28. Schmitz-Valckenberg S, Fleckenstein M, Zouache MA, Pfau M, Pappas C, Hageman JL, Agrn E, Malley C, Keenan TDL, Chew EY, Hageman GS (2022). Progression of Age-Related Macular Degeneration Among Individuals Homozygous for Risk Alleles on Chromosome 1 (CFH-CFHR5) or Chromosome 10 (ARMS2/HTRA1) or Both. JAMA Ophthalmol, 140(3), 252-260. (Read full publication)
    29. Holz FG, Schmitz-Valckenberg S, Wolf A, Agostini H, Lorenz K, Pielen A, Feltgen N, Guthoff R, Quiering C, Clemens A, Jaeger K (2022). A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration-the FALCON study. Graefes Arch Clin Exp Ophthalmol. (Read full publication)
    30. Rieck S, Kilgus S, Meyer JH, Huang H, Zhao L, Matthey M, Wang X, Schmitz-Valckenberg S, Fleischmann BK, Wenzel D (2021). Inhibition of Vascular Growth by Modulation of the Anandamide/Fatty Acid Amide Hydrolase Axis. Arterioscler Thromb Vasc Biol, 41(12), 2974-2989. (Read full publication)
    31. Knzel SH, Lindner M, Sassen J, Mller PT, Goerdt L, Schmid M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M, Pfau M (2022). Association of Reading Performance in Geographic Atrophy Secondary to Age-Related Macular Degeneration With Visual Function and Structural Biomarkers. JAMA Ophthalmol, 139(11), 1191-1199. (Read full publication)
    32. Pfau M, van Dijk EHC, van Rijssen TJ, Schmitz-Valckenberg S, Holz FG, Fleckenstein M, Boon CJF (2021). Estimation of current and post-treatment retinal function in chronic central serous chorioretinopathy using artificial intelligence. Sci Rep, 11(1), 20446. (Read full publication)
    33. Behning C, Fleckenstein M, Pfau M, Adrion C, Goerdt L, Lindner M, Schmitz-Valckenberg S, Holz FG, Schmid M (2021). Modeling of atrophy size trajectories: variable transformation, prediction and age-of-onset estimation. BMC Med Res Methodol, 21(1), 170. (Read full publication)
    34. von der Emde L, Pfau M, Holz FG, Fleckenstein M, Kortuem K, Keane PA, Rubin DL, Schmitz-Valckenberg S (2021). AI-based structure-function correlation in age-related macular degeneration. Eye (Lond), 35(8), 2110-2118. (Read full publication)
    35. Schmitz-Valckenberg S, Braun MD, Thiele S, Ferrara D, Honigberg L, Gao SS, Chen H, Steffen V, Holz FG, Samannshausen M (2021). Conversion from Intermediate Age-Related Macular Degeneration to Geographic Atrophy in a Proxima B Subcohort Using a Multimodal Approach. Ophthalmologica, 244(6), 523-534. (Read full publication)
    36. Pfau M, Sahu S, Rupnow RA, Romond K, Millet D, Holz FG, Schmitz-Valckenberg S, Fleckenstein M, Lim JI, de Sisternes L, Leng T, Rubin DL, Hallak JA (2021). Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration. Transl Vis Sci Technol, 10(7), 30. (Read full publication)
    37. Fleckenstein M, Keenan TDL, Guymer RH, Chakravarthy U, Schmitz-Valckenberg S, Klaver CC, Wong WT, Chew EY (2021). Age-related macular degeneration. Nat Rev Dis Primers, 7(1), 31. (Read full publication)
    38. Holz FG, Oleksy P, Ricci F, Kaiser PK, Kiefer J, Schmitz-Valckenberg S, COLUMBUS-AMD Study Group (2021). Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmology, 129, 54-63. (Read full publication)
    39. Pfau M, Jolly JK, Wu Z, Denniss J, Lad EM, Guymer RH, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2020). Fundus-controlled perimetry (microperimetry): Application as outcome measure in clinical trials. Prog Retin Eye Res, 82, 100907. (Read full publication)
    40. Wu Z, Pfau M, Blodi BA, Holz FG, Jaffe GJ, Liakopoulos S, Sadda SR, Staurenghi G, Bjelopera E, Brown T, Chang P, Choong J, Corradetti G, Corvi F, Domalpally A, Hurtenbach C, Nittala MG, Olson A, Pak JW, Pappe J, Samannshausen M, Skalak C, Thiele S, Guymer RH, Schmitz-Valckenberg S (2021). OCT Signs of Early Atrophy in Age-Related Macular Degeneration: Interreader Agreement: Classification of Atrophy Meetings Report 6. Ophthalmol Retina, 6, 4-14. (Read full publication)
    41. Samannshausen M, Zhou J, Pfau M, Thiele S, Steinberg J, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2020). Longitudinal Analysis of Retinal Thickness and Retinal Function in Eyes with Large Drusen Secondary to Intermediate Age-Related Macular Degeneration. Ophthalmol Retina, 5(3), 241-250. (Read full publication)
    42. Schmitz-Valckenberg S, Pfau M, Fleckenstein M, Staurenghi G, Sparrow JR, Bindewald-Wittich A, Spaide RF, Wolf S, Sadda SR, Holz FG (2020). Fundus autofluorescence imaging. Prog Retin Eye Res, 81, 100893. (Read full publication)
    43. Barkana Y, Pondorfer SG, Schmitz-Valckenberg S, Russ H, Finger RP (2021). Improved sensitivity of microperimetric outcomes for clinical studies in age-related macular degeneration. Sci Rep, 11(1), 4764. (Read full publication)
    44. Mller PL, Pfau M, Schmitz-Valckenberg S, Fleckenstein M, Holz FG (2020). Optical Coherence Tomography-Angiography in Geographic Atrophy. Ophthalmologica, 244(1), 42-50. (Read full publication)
    45. Huss MB, Schmitz-Valckenberg S, Finger RP, Lffler KU, Fleckenstein M, Holz FG, Pfau M (2020). The Willingness of Patients to Participate in an Eye Donation Registry for Research. Ophthalmologica, 244(3), 179-186. (Read full publication)
    46. Jaffe GJ, Chakravarthy U, Freund KB, Guymer RH, Holz FG, Liakopoulos S, Mons JM, Rosenfeld PJ, Sadda SR, Sarraf D, Schmitz-Valckenberg S, Spaide RF, Staurenghi G, Tufail A, Curcio CA (2020). Imaging Features Associated with Progression to Geographic Atrophy in Age-Related Macular Degeneration: Classification of Atrophy Meeting Report 5. Ophthalmol Retina, 5, 855-867. (Read full publication)
    47. Pfau M, von der Emde L, de Sisternes L, Hallak JA, Leng T, Schmitz-Valckenberg S, Holz FG, Fleckenstein M, Rubin DL (2020). Progression of Photoreceptor Degeneration in Geographic Atrophy Secondary to Age-related Macular Degeneration. JAMA Ophthalmol, 138(10), 1026-1034. (Read full publication)
    48. Pfau M, Walther G, von der Emde L, Berens P, Faes L, Fleckenstein M, Heeren TFC, Kortm K, Knzel SH, Mller PL, Maloca PM, Waldstein SM, Wintergerst MWM, Schmitz-Valckenberg S, Finger RP, Holz FG (2020). [Artificial intelligence in ophthalmology : Guidelines for physicians for the critical evaluation of studies]. Ophthalmologe, 117(10), 973-988. (Read full publication)
    49. Pfau M, von der Emde L, Dysli C, Mller PT, Thiele S, Lindner M, Schmid M, Rubin DL, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2020). Determinants of Cone and Rod Functions in Geographic Atrophy: AI-Based Structure-Function Correlation. Am J Ophthalmol, 217, 162-173. (Read full publication)
    50. Sassmannshausen M, Pfau M, Thiele S, Fimmers R, Steinberg JS, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2020). Longitudinal Analysis of Structural and Functional Changes in Presence of Reticular Pseudodrusen Associated With Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci, 61(10), 19. (Read full publication)
    51. Terheyden JH, Holz FG, Schmitz-Valckenberg S, Lning A, Schmid M, Rubin GS, Dunbar H, Tufail A, Crabb DP, Binns A, Snchez CI, Hoyng C, Margaron P, Zakaria N, Durbin M, Luhmann U, Zamiri P, Cunha-Vaz J, Martinho C, Leal S, Finger RP, MACUSTAR consortium (2020). Clinical study protocol for a low-interventional study in intermediate age-related macular degeneration developing novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention-MACUSTAR. Trials, 21(1), 659. (Read full publication)
    52. Wachtlin J, Spital G, Schmitz-Valckenberg S, Liakopoulos S, Vgeler J, Mller B, Ziemssen F, Ocean Study Group (2020). Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany. J Ophthalmol, 2020, 8024258. (Read full publication)
    53. Berger M, Schmid M, Welchowski T, Schmitz-Valckenberg S, Beyersmann J (2018). Subdistribution hazard models for competing risks in discrete time. Biostatistics, 21(3), 449-466. (Read full publication)
    54. Meyer JH, Marx J, Strack C, Holz FG, Schmitz-Valckenberg S (2020). Imaging of Therapeutic Effects of Anti-Vascular Endothelial Growth Factor Inhibitors by Optical Coherence Tomography Angiography in a Rat Model. Transl Vis Sci Technol, 9(7), 29. (Read full publication)
    55. Holekamp N, Wykoff CC, Schmitz-Valckenberg S, Mons J, Souied EH, Lin H, Rabena MD, Cantrell RA, Henry EC, Tang F, Swaminathan B, Martin J, Ferrara D, Staurenghi G (2019). Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials. Ophthalmology, 127(6), 769-783. (Read full publication)
    56. Raber FP, Reinking K, Schmitz-Valckenberg S, Althaus K, Kaut O, Witry M, Lang GE (2020). [Successful Systemic Lysis Therapy in Acute Retinal Arterial Occlusions]. Klin Monbl Augenheilkd, 237(6), 772-779. (Read full publication)
    57. Knzel SH, Mller PT, Lindner M, Goerdt L, Nadal J, Schmid M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M, Pfau M (2020). Determinants of Quality of Life in Geographic Atrophy Secondary to Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci, 61(5), 63. (Read full publication)
    58. Pielen A, Feltgen N, Hattenbach LO, Hoerauf H, Bertelmann T, Quiering C, Vgeler J, Priglinger S, Lang GE, Schmitz-Valckenberg S, Wolf A, Rehak M (2019). Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion: Post-hoc Analysis from the COMRADE Trials. Curr Eye Res, 45(5), 604-614. (Read full publication)
    59. Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, Waheed NK, Chakravarthy U, Rosenfeld PJ, Holz FG, Souied EH, Cohen SY, Querques G, Ohno-Matsui K, Boyer D, Gaudric A, Blodi B, Baumal CR, Li X, Coscas GJ, Brucker A, Singerman L, Luthert P, Schmitz-Valckenberg S, Schmidt-Erfurth U, Grossniklaus HE, Wilson DJ, Guymer R, Yannuzzi LA, Chew EY, Csaky K, Mons JM, Pauleikhoff D, Tadayoni R, Fujimoto J (2019). Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology, 127(5), 616-636. (Read full publication)
    60. Schmitz-Valckenberg S, Brasse K, Hoerauf H (2020). [Vitreous floaters]. Ophthalmologe, 117(5), 485-496. (Read full publication)
    61. Wintergerst MWM, Gorgi Zadeh S, Wiens V, Thiele S, Schmitz-Valckenberg S, Holz FG, Finger RP, Schultz T (2020). Replication and Refinement of an Algorithm for Automated Drusen Segmentation on Optical Coherence Tomography. Sci Rep, 10(1), 7395. (Read full publication)
    62. Thiele S, Nadal J, Pfau M, Samannshausen M, Fleckenstein M, Holz FG, Schmid M, Schmitz-Valckenberg S (2020). Prognostic value of intermediate age-related macular degeneration phenotypes for geographic atrophy progression. Br J Ophthalmol. (Read full publication)
    63. Schmitz-Valckenberg S, Khlewein L, Waldstein SM, Spital G, Ziemssen F, Liakopoulos S (2020). Second Opinion in Retinal Imaging. Ophthalmologe, 117(4), 326-330.
    64. Gale RP, Pearce I, Eter N, Ghanchi F, Holz FG, Schmitz-Valckenberg S, Balaskas K, Burton BJL, Downes SM, Eleftheriadis H, George S, Gilmour D, Hamilton R, Lotery AJ, Patel N, Prakash P, Santiago C, Thomas S, Varma D, Walters G, Williams M, Wolf A, Zakri RH, Igwe F, Ayan F (2019). Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. Br J Ophthalmol, 104(4), 493-499. (Read full publication)
    65. Guymer RH, Rosenfeld PJ, Curcio CA, Holz FG, Staurenghi G, Freund KB, Schmitz-Valckenberg S, Sparrow J, Spaide RF, Tufail A, Chakravarthy U, Jaffe GJ, Csaky K, Sarraf D, Mons JM, Tadayoni R, Grunwald J, Bottoni F, Liakopoulos S, Pauleikhoff D, Pagliarini S, Chew EY, Viola F, Fleckenstein M, Blodi BA, Lim TH, Chong V, Lutty J, Bird AC, Sadda SR (2019). Incomplete Retinal Pigment Epithelial and Outer Retinal Atrophy in Age-Related Macular Degeneration: Classification of Atrophy Meeting Report 4. Ophthalmology, 127(3), 394-409. (Read full publication)
    66. Pfau M, Mller PT, Knzel SH, von der Emde L, Lindner M, Thiele S, Dysli C, Nadal J, Schmid M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (2019). Type 1 Choroidal Neovascularization Is Associated with Reduced Localized Progression of Atrophy in Age-Related Macular Degeneration. Ophthalmol Retina, 4(3), 238-248. (Read full publication)
    67. Liakopoulos S, Spital G, Brinkmann CK, Schick T, Ziemssen F, Voegeler J, Koch M, Kirchhof B, Holz FG, Pauleikhoff D, Schmitz-Valckenberg S (2020). ORCA study: real-world versus reading centre assessment of disease activity of neovascular age-related macular degeneration (nAMD). Br J Ophthalmol. (Read full publication)
    68. Thiele S, Nadal J, Pfau M, Samannshausen M, von der Emde L, Fleckenstein M, Holz FG, Schmid M, Schmitz-Valckenberg S, Molecular Diagnostic of Age-related Macular Degeneration Study Group (2019). Prognostic Value of Retinal Layers in Comparison with Other Risk Factors for Conversion of Intermediate Age-related Macular Degeneration. Ophthalmol Retina, 4(1), 31-40. (Read full publication)
    69. von der Emde L, Thiele S, Pfau M, Nadal J, Meyer J, Mller PT, Schmid M, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2019). Assessment of Exudative Activity of Choroidal Neovascularization in Age-Related Macular Degeneration by OCT Angiography. Ophthalmologica, 243(2), 120-128. (Read full publication)
    70. Pfau M, Mller PL, von der Emde L, Lindner M, Mller PT, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2018). MESOPIC AND DARK-ADAPTED TWO-COLOR FUNDUS-CONTROLLED PERIMETRY IN GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina, 40(1), 169-180. (Read full publication)
    71. Terheyden JH, Finger RP, Schmitz-Valckenberg S, Agostini H, Dahlke C, Kuehlewein L, Lang GE, Pauleikhoff D, Wolf A, Boettger MK, Luhmann UFO, Asmus F, Holz FG, MACUSTAR-Konsortium (2019). [Development and validation of novel clinical endpoints in intermediate age-related macular degeneration in MACUSTAR]. Ophthalmologe, 116(12), 1186-1193. (Read full publication)
    72. Callizo J, Ziemssen F, Bertelmann T, Feltgen N, Vgeler J, Koch M, Eter N, Liakopoulos S, Schmitz-Valckenberg S, Spital G (2019). Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study. Clin Ophthalmol, 13, 2167-2179. (Read full publication)
    73. Pfau M, von der Emde L, Dysli C, Thiele S, Mller PT, Lindner M, Nadal J, Schmid M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (2019). Light Sensitivity Within Areas of Geographic Atrophy Secondary to Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci, 60(12), 3992-4001. (Read full publication)
    74. Fleckenstein M, Thiele S, Pfau M, Schmitz-Valckenberg S, Holz FG (2019). [Dry Age-Related Macular Degeneration - Epidemiology and Classification]. Klin Monbl Augenheilkd, 236(9), 1068-1075. (Read full publication)
    75. Pfau M, Lindner M, Goerdt L, Thiele S, Nadal J, Schmid M, Schmitz-Valckenberg S, Sadda SR, Holz FG, Fleckenstein M, Fundus Autofluorescence in Age-Related Macular Degeneration Study Group (2018). PROGNOSTIC VALUE OF SHAPE-DESCRIPTIVE FACTORS FOR THE PROGRESSION OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina, 39(8), 1527-1540. (Read full publication)
    76. von der Emde L, Pfau M, Dysli C, Thiele S, Mller PT, Lindner M, Schmid M, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2019). Artificial intelligence for morphology-based function prediction in neovascular age-related macular degeneration. Sci Rep, 9(1), 11132. (Read full publication)
    77. Meyer JH, Larsen PP, Strack C, Harmening WM, Krohne TU, Holz FG, Schmitz-Valckenberg S (2019). Optical coherence tomography angiography (OCT-A) in an animal model of laser-induced choroidal neovascularization. Exp Eye Res, 184, 162-171. (Read full publication)
    78. Gattoussi S, Buitendijk GHS, Peto T, Leung I, Schmitz-Valckenberg S, Oishi A, Wolf S, Dek G, Delcourt C, Klaver CCW, Korobelnik JF, European Eye Epidemiology E3 consortium (2018). The European Eye Epidemiology spectral-domain optical coherence tomography classification of macular diseases for epidemiological studies. Acta Ophthalmol, 97(4), 364-371. (Read full publication)
    79. Grassmann F, Harsch S, Brandl C, Kiel C, Nrnberg P, Toliat MR, Fleckenstein M, Pfau M, Schmitz-Valckenberg S, Holz FG, Chew EY, Swaroop A, Ratnapriya R, Klein ML, Mulyukov Z, Zamiri P, Weber BHF (2019). Assessment of Novel Genome-Wide Significant Gene Loci and Lesion Growth in Geographic Atrophy Secondary to Age-Related Macular Degeneration. JAMA Ophthalmol. (Read full publication)
    80. Lindner M, Pfau M, Czauderna J, Goerdt L, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (2018). Determinants of Reading Performance in Eyes with Foveal-Sparing Geographic Atrophy. Ophthalmol Retina, 3(3), 201-210. (Read full publication)
    81. Brasse K, Schmitz-Valckenberg S, Jnemann A, Roider J, Hoerauf H (2018). [YAG laser vitreolysis for treatment of symptomatic vitreous opacities]. Ophthalmologe, 116(1), 73-84. (Read full publication)
    82. Finger RP, Schmitz-Valckenberg S, Schmid M, Rubin GS, Dunbar H, Tufail A, Crabb DP, Binns A, Snchez CI, Margaron P, Normand G, Durbin MK, Luhmann UFO, Zamiri P, Cunha-Vaz J, Asmus F, Holz FG, onbehalfoftheMACUSTARconsortium (2018). MACUSTAR: Development and Clinical Validation of Functional, Structural, and Patient-Reported Endpoints in Intermediate Age-Related Macular Degeneration. Ophthalmologica, 241(2), 61-72. (Read full publication)
    83. Fang PP, Domdei N, Herrmann P, Schmitz-Valckenberg S, Holz FG, Harmening WM, Krohne TU (2017). MINIMAL OPTICAL COHERENCE TOMOGRAPHY B-SCAN DENSITY FOR RELIABLE DETECTION OF INTRARETINAL AND SUBRETINAL FLUID IN MACULAR DISEASES. Retina, 39(1), 150-156. (Read full publication)
    84. Ziemssen F, Wachtlin J, Kuehlewein L, Gamulescu MA, Bertelmann T, Feucht N, Voegeler J, Koch M, Liakopoulos S, Schmitz-Valckenberg S, Spital G, OCEAN study group (2018). Intravitreal Ranibizumab Therapy for Diabetic Macular Edema in Routine Practice: Two-Year Real-Life Data from a Non-interventional, Multicenter Study in Germany. Diabetes Ther, 9(6), 2271-2289. (Read full publication)
    85. Pfau M, Lindner M, Gliem M, Steinberg JS, Thiele S, Finger RP, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2018). Mesopic and dark-adapted two-color fundus-controlled perimetry in patients with cuticular, reticular, and soft drusen. Eye (Lond), 32(12), 1819-1830. (Read full publication)
    86. Feltgen N, Hattenbach LO, Bertelmann T, Callizo J, Rehak M, Wolf A, Berk H, Eter N, Lang GE, Pielen A, Schmitz-Valckenberg S, Quiering C, Rose U, Hoerauf H, COMRADE Study Group (2018). Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study. Acta Ophthalmol, 96(8), e933-e941. (Read full publication)
    87. Brinkmann CK, Chang P, Schick T, Heimes B, Vgeler J, Haegele B, Kirchhof B, Holz FG, Pauleikhoff D, Ziemssen F, Liakopoulos S, Spital G, Schmitz-Valckenberg S (2018). Initial diagnosis and indication for anti-vascular endothelial growth factor therapy in retinal diseases. Ophthalmologe.
    88. Mller PL, Pfau M, Mauschitz MM, Mller PT, Birtel J, Chang P, Gliem M, Schmitz-Valckenberg S, Fleckenstein M, Holz FG, Herrmann P (2018). Comparison of Green Versus Blue Fundus Autofluorescence in ABCA4-Related Retinopathy. Transl Vis Sci Technol, 7(5), 13. (Read full publication)
    89. Paul C, Krug P, Muller HH, Wachtlin J, Mennel S, Muller S, Schmitz-Valckenberg S, Bertelmann T, Schumann RG (2018). Comparison of the horizontal diameter to a modeled area of traction in eyes with vitreomacular traction: is the diameter close enough to the truth? Graefes Arch Clin Exp Ophthalmol, 256(10), 1817-1822. (Read full publication)
    90. Pfau M, Lindner M, Steinberg JS, Thiele S, Brinkmann CK, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2018). Visual field indices and patterns of visual field deficits in mesopic and dark-adapted two-colour fundus-controlled perimetry in macular diseases. Br J Ophthalmol, 102(8), 1054-1059. (Read full publication)
    91. Paul C, Heun C, Mller HH, Hoerauf H, Feltgen N, Wachtlin J, Kaymak H, Mennel S, Koss MJ, Fauser S, Maier MM, Schumann RG, Mueller S, Chang P, Schmitz-Valckenberg S, Kazerounian S, Szurman P, Lommatzsch A, Bertelmann T (2018). Calculating the individual probability of successful ocriplasmin treatment in eyes with VMT syndrome: a multivariable prediction model from the EXPORT study. Br J Ophthalmol, 102(8), 1092-1097. (Read full publication)
    92. Welker SG, Pfau M, Heinemann M, Schmitz-Valckenberg S, Holz FG, Finger RP (2018). Retest Reliability of Mesopic and Dark-Adapted Microperimetry in Patients With Intermediate Age-Related Macular Degeneration and Age-Matched Controls. Invest Ophthalmol Vis Sci, 59(4), AMD152-AMD159. (Read full publication)
    93. Mller PL, Pfau M, Mller PT, Nadal J, Schmid M, Lindner M, de Sisternes L, Sthr H, Weber BHF, Neuhaus C, Herrmann P, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (2018). Choroidal Flow Signal in Late-Onset Stargardt Disease and Age-Related Macular Degeneration: An OCT-Angiography Study. Invest Ophthalmol Vis Sci, 59(4), AMD122-AMD131. (Read full publication)
    94. Lindner M, Kosanetzky S, Pfau M, Nadal J, Gordt LA, Schmitz-Valckenberg S, Schmid M, Holz FG, Fleckenstein M (2018). Local Progression Kinetics of Geographic Atrophy in Age-Related Macular Degeneration Are Associated With Atrophy Border Morphology. Invest Ophthalmol Vis Sci, 59(4), AMD12-AMD18. (Read full publication)
    95. Thiele S, Pfau M, Larsen PP, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2018). Multimodal Imaging Patterns for Development of Central Atrophy Secondary to Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci, 59(4), AMD1-AMD11. (Read full publication)
    96. Sassmannshausen M, Steinberg JS, Fimmers R, Pfau M, Thiele S, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2018). Structure-Function Analysis in Patients With Intermediate Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci, 59(3), 1599-1608. (Read full publication)
    97. Hattenbach LO, Feltgen N, Bertelmann T, Schmitz-Valckenberg S, Berk H, Eter N, Lang GE, Rehak M, Taylor SR, Wolf A, Weiss C, Paulus EM, Pielen A, Hoerauf H (2018). Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmol, 96(1), e10-e18. (Read full publication)
    98. von der Emde L, Pfau M, Thiele S, Mller PT, Hassenrik R, Fleckenstein M, Holz FG, Schmitz-Valckenberg S (2018). Mesopic and Dark-Adapted Two-Color Fundus-Controlled Perimetry in Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Transl Vis Sci Technol, 8(1), 7. (Read full publication)

    Review

    1. Huang A, Wu Z, Ansari G, Von Der Emde L, Pfau M, Schmitz-Valckenberg S, Fleckenstein M, Keenan TDL, Sadda SR, Guymer RH, Cheung CMG, Chakravarthy U (2025). Geographic atrophy: Understanding the relationship between structure and function. [Review]. Asia Pac J Ophthalmol (Phila), 14(3), 100207. (Read full publication)
    2. Terheyden JH, Dunbar HMP, Schmitz-Valckenberg S, Behning C, Martinho C, Luhmann UFO, Samannshausen M, Lning A, Miliu A, Aires ID, Basile PG, Batuca J, Schmid M, Moll KP, Zakaria N, Tufail A, Binns A, Crabb DP, Leal S, Finger RP, Holz FG, MACUSTAR consortium (2025). Validating candidate endpoints for intermediate age-related macular degeneration trials in a multi-centre setting-lessons from the MACUSTAR study. [Review]. Eye (Lond). (Read full publication)
    3. Broadbent E, Knzel SH, Pfau M, Schmitz-Valckenberg S, Fleckenstein M (2024). Age-related macular degeneration: natural history revisited in geographic atrophy. [Review]. Eye (Lond), 39(2), 217-227. (Read full publication)
    4. Chang P, von der Emde L, Pfau M, Knzel S, Fleckenstein M, Schmitz-Valckenberg S, Holz FG (2024). [Use of artificial intelligence in geographic atrophy in age-related macular degeneration]. [Review]. Ophthalmologie, 121(8), 616-622. (Read full publication)
    5. Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U (2024). Age-Related Macular Degeneration: A Review. [Review]. JAMA, 331(2), 147-157. (Read full publication)
    6. Pfau M, Knzel SH, Pfau K, Schmitz-Valckenberg S, Fleckenstein M, Holz FG (2023). Multimodal imaging and deep learning in geographic atrophy secondary to age-related macular degeneration. [Review]. Acta Ophthalmol, 101(8), 881-890. (Read full publication)
    7. Kaiser PK, Schmitz-Valckenberg MS, Holz FG (2022). ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR BIOSIMILARS IN OPHTHALMOLOGY. [Review]. Retina, 42(12), 2243-2250. (Read full publication)
    8. Terheyden JH, Schmitz-Valckenberg S, Crabb DP, Dunbar H, Luhmann UFO, Behning C, Schmid M, Silva R, Cunha-Vaz J, Tufail A, Weissgerber G, Leal S, Holz FG, Finger RP, onbehalfoftheMACUSTARConsortium (2020). Use of Composite End Points in Early and Intermediate Age-Related Macular Degeneration Clinical Trials: State-of-the-Art and Future Directions. [Review]. Ophthalmologica, 244(5), 387-395. (Read full publication)
    9. Mller PL, Wolf S, Dolz-Marco R, Tafreshi A, Schmitz-Valckenberg S, Holz FG, Bille JF (2019). Ophthalmic Diagnostic Imaging: Retina. [Review]. (Read full publication)

    Conference Proceedings

    1. Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, Blodi BA, Bottoni F, Chakravarthy U, Chew EY, Csaky K, Danis RP, Fleckenstein M, Freund KB, Grunwald J, Hoyng CB, Jaffe GJ, Liakopoulos S, Mons JM, Pauleikhoff D, Rosenfeld PJ, Sarraf D, Spaide RF, Tadayoni R, Tufail A, Wolf S, Staurenghi G (2018). Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3. Ophthalmology, United States, 125(4), 537-548. (Read full publication)

    Editorial

    1. Holz FG, Schmitz-Valckenberg S (2024). [Artificial intelligence (AI) in age-related macular degeneration]. Ophthalmologie, 121(8), 607-608. (Read full publication)

    Letter

    1. Pfau M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (2022). Re: Trivizki et al. Local Geographic Atrophy Growth Rates Not Influenced by Close Proximity to Non-Exudative Type 1 Macular Neovascularization. [Letter to the editor]. Invest Ophthalmol Vis Sci, 63(5), 10. (Read full publication)

    Other

    1. Garzone D, Terheyden JH, Morelle O, Wintergerst MWM, Samannshausen M, Schmitz-Valckenberg S, Pfau M, Thiele S, Poor S, Leal S, Holz FG, Finger RP, MACUSTAR Consortium (2023). Author Correction: Comparability of automated drusen volume measurements in age-related macular degeneration: a MACUSTAR study report. Sci Rep (13(1), p. 3795). England. (Read full publication)